Leading Experts on Migraine and Headache Therapy Will Present the Results of the Multicenter Post-Registration Observational Study “EXPERIENCE” on the Use of Rizatriptan in Patients at the 15th Manage Pain Congress Launched in Moscow

ONLY FOR HEALTHCARE PROFESSIONALS

On November 5, 2024, the anniversary 15^th Manage Pain Congress opened in Moscow. NovaMedica is supporting one of the most important interdisciplinary events for the medical community aimed at exchanging advanced knowledge and experience in organizing care and treatment for patients suffering from various pain syndromes.

With the support of NovaMedica, a symposium titled “Relonova in Real Clinical Practice: What Have Observational Studies Shown?” will be held as part of the Congress on November 5 at 10:45 a.m. in the Endorphin Hall. The symposium will include the presentation and discussion of the results of the multicenter post-registration observational study EXPERIENCE aimed at examination of the efficacy and safety of Relonova^® (INN Rizatriptan) in patients with migraine. Renowned experts in migraine and headache therapy will share their experience and talk about the results of the program with their colleagues.

	The principal researcher of the EXPERIENCE program, Guzyal TABEEVA, Doctor of Medical Sciences, Professor of the Department of Nervous Diseases of the I.M. Sechenov First Moscow State Medical University, President of the Russian Society for the Study of Headache, member of the Council of Experts of the Association of Interdisciplinary Medicine, will present a report titled “EXPERIENCE of Using Rizatriptan in Tablets in Patients with Migraine.”
	Elena FILATOVA, Doctor of Medical Sciences, Professor of the Department of Nervous Diseases of the Institute of Postgraduate Education, I.M. Sechenov First Moscow State Medical University, will talk about the part of the study that was conducted at the Academician A. Vein Neurology Clinic for the Treatment of Headaches and Vegetative Disorders in her presentation “Effective Relief of a Migraine Attack: Consensus Criteria in Real Clinical Practice.”
	Alexey DANILOV, Doctor of Medical Sciences, Head of the Department of Nervous Diseases of the Institute of Postgraduate Education, I.M. Sechenov First Moscow State Medical University, Director of the Institute of Interdisciplinary Medicine, will moderate the discussion and help its participants assess the importance of the new research data to ensure better care for patients suffering from migraine.

A lecture dedicated to a detailed presentation of the results of the study “Rizatriptan in Tablets (Relonova®): Results of the First Russian Observational Program” will be held on November 6 at 3:45 p.m. in the Endorphin Hall. It will be presented by Nina LATYSHEVA, Doctor of Medical Sciences, Professor of the Department of Nervous Diseases of the Institute of Postgraduate Education, I.M. Sechenov First Moscow State Medical University, neurologist at the Academician A. Vein Neurology Clinic for the Treatment of Headaches and Vegetative Disorders.

The Congress will be held from November 5 to November 7 at Azimut City Hotel Olympic (18/1 Olimpiysky Prospekt). In addition to the offline event, an online broadcast will also be available.

For registration to participate offline or access the online broadcast, as well as for detailed information on the program, please visit https://managepain.ru/events/kongress-2024/